← Leaderboards
Kevin M Flanigan
Research Inst Nationwide Children'S Hosp
$19,837,604
Attributed
$26,448,109
Total exposure
29
Grants
23
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$36,835,033 · 31
By mechanism
R01$17,418,700 · 3
P50$13,441,867 · 6
U01$4,349,431 · 1
R21$526,240 · 1
R61$519,166 · 1
M01$315,029 · 18
Top collaborators
- Robert B Weiss9 shared
- Haiyan Fu5 shared
- Veronica J. Vieland4 shared
Most similar at Research Inst Nationwide Children'S Hosp
Same institution · by research overlap
- Scott Q Harper$9,530,406
Others in their field
Top investigators on “Dystrophin”
- Jeffrey S Chamberlain · University Of Michigan At Ann Arbor$43,696,384
- James M Ervasti · University Of Wisconsin Madison$18,166,626
- Elizabeth M McNally · University Of Chicago$15,033,035
- Krista H Vandenborne · University Of Pennsylvania$13,932,898
- Dongsheng Duan · University Of Florida$13,861,127
- Hansell H Stedman · University Of Pennsylvania$12,563,636
Research focus
DystrophinGenesMuscular DystrophiesMutationProteinsExonsResearch PersonnelMuscleClinical TrialsDuchenne Muscular DystrophyGene TherapyResourcesRna SplicingUnited States National Institutes Of HealthPhenotypeMolecularProgramsVectorPrincipal InvestigatorUniversitiesFundingMyopathyTherapy DevelopmentMyoblasts
Grant awards (70)
MDSRC for Next Directions in Muscular Dystrophy Research$1,513,648
P50 · FY2025 · HD · contact PI
Genetic modifiers of Duchenne Muscular Dystrophy$921,491
R01 · FY2025 · NS · contact PI
Preclinical development of DMD exon 44 skipping using AAV.U7snRNA: a versatile tool that can help 6-12% of DMD patient$519,166
R61 · FY2025 · NS · contact PI
Molecular Mechanisms of Dystrophin Expression in Ameliorated Phenotypes$445,145
R01 · FY2025 · NS · contact PI
(Project 2) Development of U7snRNA Vectors for Dystrophinopathy$337,741
P50 · FY2025 · HD · contact PI
MDSRC Administrative Core$145,228
P50 · FY2025 · HD · contact PI
MDSRC for Next Directions in Muscular Dystrophy Research$1,557,819
P50 · FY2024 · HD · contact PI
Genetic modifiers of Duchenne Muscular Dystrophy$904,269
R01 · FY2024 · NS · contact PI
Molecular Mechanisms of Dystrophin Expression in Ameliorated Phenotypes$440,738
R01 · FY2024 · NS · contact PI
(Project 2) Development of U7snRNA Vectors for Dystrophinopathy$351,482
P50 · FY2024 · HD · contact PI
MDSRC Administrative Core$145,228
P50 · FY2024 · HD · contact PI
Genetic modifiers of Duchenne Muscular Dystrophy$932,236
R01 · FY2023 · NS · contact PI
Molecular Mechanisms of Dystrophin Expression in Ameliorated Phenotypes$454,369
R01 · FY2023 · NS · contact PI
Genetic modifiers of Duchenne Muscular Dystrophy$946,236
R01 · FY2022 · NS · contact PI
Center of Research Translation in Muscular Dystrophy Therapeutic Development$1,417,545
P50 · FY2020 · AR · contact PI
Project 3: Use of an IRES-driven N-truncated dystrophin isoform as a clinical therapy for 5 mutations in the dystrophinopathies$299,585
P50 · FY2020 · AR · contact PI
Administrative Core$138,352
P50 · FY2020 · AR · contact PI
Center of Research Translation in Muscular Dystrophy Therapeutic Development$1,443,070
P50 · FY2019 · AR · contact PI
Project 3: Use of an IRES-driven N-truncated dystrophin isoform as a clinical therapy for 5 mutations in the dystrophinopathies$283,862
P50 · FY2019 · AR · contact PI
Administrative Core$214,352
P50 · FY2019 · AR · contact PI
Center of Research Translation in Muscular Dystrophy Therapeutic Development$1,467,854
P50 · FY2018 · AR · contact PI
Genetic modifiers of Duchenne Muscular Dystrophy$569,855
R01 · FY2018 · NS · contact PI
Project 3: Use of an IRES-driven N-truncated dystrophin isoform as a clinical therapy for 5 mutations in the dystrophinopathies$287,046
P50 · FY2018 · AR · contact PI
Administrative Core$214,353
P50 · FY2018 · AR · contact PI
Center of Research Translation in Muscular Dystrophy Therapeutic Development$1,487,033
P50 · FY2017 · AR · contact PI
Genetic modifiers of Duchenne Muscular Dystrophy$774,783
R01 · FY2017 · NS · contact PI
Project 3: Use of an IRES-driven N-truncated dystrophin isoform as a clinical therapy for 5 mutations in the dystrophinopathies$337,725
P50 · FY2017 · AR · contact PI
First-in-Human rAAVrh74.MCK.GALGT2 DMD Clinical Trial$263,120
R21 · FY2017 · AR · contact PI
Center of Research Translation in Muscular Dystrophy Therapeutic Development$1,499,955
P50 · FY2016 · AR · contact PI
Genetic modifiers of Duchenne Muscular Dystrophy$774,783
R01 · FY2016 · NS · contact PI
Project 3: Use of an IRES-driven N-truncated dystrophin isoform as a clinical therapy for 5 mutations in the dystrophinopathies$299,989
P50 · FY2016 · AR · contact PI
Genetic modifiers of Duchenne Muscular Dystrophy$825,435
R01 · FY2015 · NS · contact PI
First-in-Human rAAVrh74.MCK.GALGT2 DMD Clinical Trial$263,120
R21 · FY2015 · AR · contact PI
Treating the CNS and Somatic Diseases of MPS IIB Systemic Gene Delivery$1,204,789
U01 · FY2014 · NS
Genetic modifiers of Duchenne Muscular Dystrophy$987,747
R01 · FY2014 · NS · contact PI
Treating the CNS and Somatic Diseases of MPS IIB Systemic Gene Delivery$1,207,188
U01 · FY2013 · NS
Treating the CNS and Somatic Diseases of MPS IIIB by Systemic Gene Delivery$167,871
U01 · FY2013 · NS
Treating the CNS and Somatic Diseases of MPS IIB Systemic Gene Delivery$879,620
U01 · FY2012 · NS
Treating the CNS and Somatic Diseases of MPS IIB Systemic Gene Delivery$889,963
U01 · FY2011 · NS
Translational Research in the Dystrophinopathies$911,883
R01 · FY2010 · NS · contact PI
Translational Research in the Dystrophinopathies$822,184
R01 · FY2009 · NS · contact PI
Translational Research in the Dystrophinopathies$265,937
R01 · FY2009 · NS · contact PI
Translational Research in the Dystrophinopathies$95,000
R01 · FY2009 · NS · contact PI
Translational Research in the Dystrophinopathies$913,423
R01 · FY2008 · NS · contact PI
CLINICAL TRIAL: NONSENSE-MUTATION-MEDIATED DUCHENNE MUSCULAR DYSTROPHY$23,124
M01 · FY2008 · RR · contact PI
GENETIC AND MOLECULAR CHARACTERIZATION OF INHERITED NEUROLOGICAL DISEASES$9,370
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: BECKER FACIOSCAPULOHUMERAL AND LIMB-GIRDLE MUSCULAR DYSTROPHY$6,017
M01 · FY2008 · RR · contact PI
STUDY OF INHERITED NEUROLOGICAL DISEASES$1,289
M01 · FY2008 · RR · contact PI
Translational Research in the Dystrophinopathies$987,153
R01 · FY2007 · NS · contact PI
NONSENSE-MUTATION-MEDIATED DUCHENNE MUSCULAR DYSTROPHY$147,293
M01 · FY2007 · RR · contact PI
Translational Research in the Dystrophinopathies$50,000
R01 · FY2007 · NS · contact PI
BECKER FACIOSCAPULOHUMERAL AND LIMB-GIRDLE MUSCULAR DYSTROPHY$38,328
M01 · FY2007 · RR · contact PI
STUDY OF INHERITED NEUROLOGICAL DISEASES$8,213
M01 · FY2007 · RR · contact PI
GENETIC AND MOLECULAR CHARACTERIZATION OF INHERITED NEUROLOGICAL DISEASES$2,190
M01 · FY2007 · RR · contact PI
Translational Research in the Dystrophinopathies$1,026,422
R01 · FY2006 · NS · contact PI
BECKER, FACIOSCAPULOHUMERAL AND LIMB-GIRDLE MUSCULAR DYSTROPHY$18,043
M01 · FY2006 · RR · contact PI
NONSENSE-MUTATION-MEDIATED DUCHENNE MUSCULAR DYSTROPHY$16,655
M01 · FY2006 · RR · contact PI
DUCHENNE MUSCULAR DYSTROPHY$16,655
M01 · FY2006 · RR · contact PI
GENETIC AND MOLECULAR CHARACTERIZATION OF INHERITED NEUROLOGICAL DISEASES$7,402
M01 · FY2006 · RR · contact PI
EVALUATION OF MUSCLE AND SKIN IN INHERITED NEUROLOGICAL DISEASES$5,552
M01 · FY2006 · RR · contact PI
TRANSLATIONAL RESEARCH IN THE DYSTROPHINOPATHIES$2,314
M01 · FY2006 · RR · contact PI
GENETIC AND MOLECULAR CHARACTERIZATION OF INHERITED NEUROLOGICAL DISEASES$5,453
M01 · FY2005 · RR
EVALUATION OF MUSCLE IN FACIOSCAPULOHUMERAL DYSTROPHY$2,936
M01 · FY2005 · RR
TRANSLATIONAL RESEARCH IN THE DYSTROPHINOPATHIES$2,517
M01 · FY2005 · RR
EVALUATION OF MUSCLE AND SKIN FOR THE STUDY OF INHERITED NEUROLOGICAL DISEASES$1,678
M01 · FY2005 · RR
Translational Research in the Dystrophinopathies$1,137,965
R01 · FY2004 · NS
Translational Research in the Dystrophinopathies$1,121,658
R01 · FY2003 · NS
Translational Research in the Dystrophinopathies$1,109,988
R01 · FY2002 · NS
MOLECULAR CHARACTERIZATION OF GIANT AXONAL NEUROPATHY$135,000
K08 · FY2001 · NS
MOLECULAR CHARACTERIZATION OF GIANT AXONAL NEUROPATHY$129,600
K08 · FY2000 · NS